MedPath

Carfilzomib

Generic Name
Carfilzomib
Brand Names
Kyprolis
Drug Type
Small Molecule
Chemical Formula
C40H57N5O7
CAS Number
868540-17-4
Unique Ingredient Identifier
72X6E3J5AR
Background

Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.

Indication

Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.

Associated Conditions
Relapsed/Refractory Multiple Myeloma (RRMM)
Associated Therapies
-

Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 1
Completed
Conditions
Acute Lymphoblastic Leukemia (ALL)
Interventions
First Posted Date
2014-12-01
Last Posted Date
2024-07-16
Lead Sponsor
Amgen
Target Recruit Count
130
Registration Number
NCT02303821
Locations
🇺🇸

Childrens Healthcare of Atlanta, Egleston, Atlanta, Georgia, United States

🇺🇸

West Virginia University Medicine Childrens, Morgantown, West Virginia, United States

🇹🇷

Medical Park Bahcelievler Hastanesi, Istanbul, Turkey

and more 116 locations

Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma

Phase 2
Conditions
Multiple Myeloma
Interventions
First Posted Date
2014-11-27
Last Posted Date
2020-08-27
Lead Sponsor
University Hospital, Lille
Target Recruit Count
80
Registration Number
NCT02302495
Locations
🇫🇷

Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France

🇫🇷

Hopital J Monod, Montivilliers, France

🇫🇷

Centre Hospitalier de la côte basque, Bayonne, France

and more 30 locations

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

First Posted Date
2014-11-19
Last Posted Date
2023-11-01
Lead Sponsor
Oncotherapeutics
Target Recruit Count
45
Registration Number
NCT02294357
Locations
🇺🇸

James R Berenson, MD, Inc., West Hollywood, California, United States

🇺🇸

Blood & Cancer Center of East Texas, Tyler, Texas, United States

🇺🇸

California Cancer Associates for Research & Excellence (cCARE), Encinitas, California, United States

and more 4 locations

Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma

Phase 1
Completed
Conditions
Contiguous Stage II Adult Lymphoblastic Lymphoma
Stage IV Adult Lymphoblastic Lymphoma
Stage III Adult Lymphoblastic Lymphoma
Noncontiguous Stage II Adult Lymphoblastic Lymphoma
Stage I Adult Lymphoblastic Lymphoma
Untreated Adult Acute Lymphoblastic Leukemia
Interventions
First Posted Date
2014-11-18
Last Posted Date
2022-03-10
Lead Sponsor
Mehrdad Abedi, MD
Target Recruit Count
10
Registration Number
NCT02293109
Locations
🇺🇸

University of California Davis, Sacramento, California, United States

Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma

Phase 1
Terminated
Conditions
Lymphoma
Interventions
Drug: Ibrutinib
Drug: Carfilzomib
Behavioral: Phone Calls
First Posted Date
2014-10-20
Last Posted Date
2019-02-28
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
8
Registration Number
NCT02269085
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

First Posted Date
2014-10-16
Last Posted Date
2020-04-17
Lead Sponsor
Incyte Corporation
Target Recruit Count
83
Registration Number
NCT02265510
Locations
🇺🇸

Site 2, Nashville, Tennessee, United States

Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Neoplasms
Malignancies
Interventions
First Posted Date
2014-10-06
Last Posted Date
2017-02-07
Lead Sponsor
Emory University
Target Recruit Count
22
Registration Number
NCT02257476
Locations
🇺🇸

Emory University Winship Cancer Institute, Atlanta, Georgia, United States

A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)

Phase 1
Terminated
Conditions
Cancer
Interventions
First Posted Date
2014-09-10
Last Posted Date
2016-05-04
Lead Sponsor
Novartis
Target Recruit Count
1
Registration Number
NCT02235740
Locations
🇺🇸

Novartis Investigative Site, Cary, North Carolina, United States

Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.

Phase 2
Active, not recruiting
Conditions
MULTIPLE MYELOMA (MM)
Interventions
First Posted Date
2014-07-30
Last Posted Date
2024-12-05
Lead Sponsor
Mario Boccadoro
Target Recruit Count
477
Registration Number
NCT02203643
Locations
🇮🇹

IRCCS--CROB --CROB di Rionero in di Rionero in Vulture, Rionero in Vulture, Italy

Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients

Phase 1
Completed
Conditions
Multiple Myeloma
Interventions
First Posted Date
2014-07-30
Last Posted Date
2023-07-03
Lead Sponsor
Stichting European Myeloma Network
Target Recruit Count
36
Registration Number
NCT02204241
Locations
🇮🇹

Fondazione EMN Italy Onlus, Torino, Italy

© Copyright 2025. All Rights Reserved by MedPath